Arcellx, Inc.
Formerly Encarta Therapeutics, Inc.
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jan 2023 | $100 M | No. 4 | $50 to $250 million | equity | SEC | |
| Feb 2022 | $10 M | No. 3 | $10 to $50 million | equity | SEC | |
| Mar 2021 | $120 M | No. 2 | $50 to $250 million | equity | SEC | |
| Aug 2019 | $43 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Arcellx, Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2023).
SEC Form D · Feb 2023
The industry group it chose in its notices: Biotechnology.
SEC Form D · Feb 2023
That is all the official record says: Arcellx, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
9 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| David Charles Lubner | Person | not stated | not stated | Held Series C preferred stock, director (Form 3, 2022) | SEC Form 3 |
| Nea 15 GP, LLC | Other | not stated | not stated | Held Series A, B-1, B-2 and C preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| NEA Partners 15, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B-1, B-2 and C preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| New Enterprise Associates 15, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B-1, B-2 and C preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| Novo Holdings A/s | Fund or asset manager | not stated | not stated | Held Series A, B-1, B-2 and C preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| SR One Capital Fund I Aggregator LP | Fund or asset manager | not stated | not stated | Held Series A, B-1, B-2 and C preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| SR One Capital Management, LLC | Fund or asset manager | not stated | not stated | Held Series A, B-1, B-2 and C preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| SR One Capital Partners I, LP | Fund or asset manager | not stated | not stated | Held Series A, B-1, B-2 and C preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| SR One Co-Invest II, LLC | Other | not stated | not stated | Held Series A, B-1, B-2 and C preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 32 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Christopher Heery | Executive officer | Feb 2023 |
| Michelle Gilson | Executive officer | Feb 2023 |
| Rami Elghandour | Executive officer | Feb 2023 |
| Lance Thibault | Executive officer | Mar 2022 |
| Han Lee | Executive officer | Jul 2021 |
| David Hilbert | Executive officer | Oct 2019 |
| Ali Behbahani | Director | Feb 2023 |
| David Lubner | Director | Feb 2023 |
| Derek Yoon | Director | Feb 2023 |
| Jill Carroll | Director | Feb 2023 |
| Kavita Patel | Director | Feb 2023 |
| Olivia Ware | Director | Feb 2023 |
| Rami Elghandour | Director | Feb 2023 |
| David T. Lubner | Director | Mar 2022 |
| Derek T. Yoon | Director | Mar 2022 |
| Lewis T. Williams | Director | Mar 2022 |
| Lewis T. Rusty Williams | Director | Jul 2021 |
| Tiba Aynechi | Director | Jul 2021 |
| David Hilbert | Director | Oct 2019 |
| Hugo Beekman | Director | Oct 2019 |
| Roger Sawhney | Director | Oct 2019 |